{"id":"W4387811453","doi":"10.1016/j.annonc.2023.09.1883","title":"697P Open-label, phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Hackensack Meridian Health; National Cancer Center Japan; Sanofi; Boehringer Ingelheim","keywords":"Medicine; Internal medicine; Adverse effect; Clinical endpoint; Discontinuation; Gastroenterology; Peripheral edema; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001055295,0.001814195,0.001969727,0.0004914166,0.0004288592,0.001436559,0.0007905538,0.001259289,0.006419164],"category_scores_gemma":[0.000530623,0.0005475378,0.001461054,0.000405436,0.001077182,0.0009665756,0.0004497654,0.004999656,0.002303118],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121451,"about_ca_system_score_gemma":0.001442713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001492332,"about_ca_topic_score_gemma":0.003542741,"domain_scores_codex":[0.9996183,0.0001304688,0.00001114129,0.00006226571,0.00004377023,0.0001341305],"domain_scores_gemma":[0.9996452,0.00005616384,0.00004427644,0.00003128124,0.00002486069,0.0001981273],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7691569,0.04860989,0.002331491,0.0006728686,0.001358672,0.0002205467,0.0001926362,0.00275995,0.02865219,0.0006729353,0.01076603,0.1346058],"study_design_scores_gemma":[0.6558179,0.3274308,0.005903253,0.00004366122,0.000435633,0.0002244629,0.00007297153,0.001940766,0.002800628,0.0003977507,0.00489318,0.00003895736],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844057,0.002759418,0.0008214594,0.001189759,0.0004330063,0.002010897,0.00201293,0.0003019267,0.006064949],"genre_scores_gemma":[0.9781838,0.002247595,0.002149364,0.001728864,0.0002884885,0.002076394,0.004526104,0.00007880815,0.008720605],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006419164,"threshold_uncertainty_score":0.02147418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06275232884655985,"score_gpt":0.4210697876618714,"score_spread":0.3583174588153115,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}